(S (NP (NNP Immunotherapy)) (VP (VBZ has) (ADVP (RB recently)) (VP (VBN shown) (NP (JJ important) (JJ clinical) (NNS successes)) (PP (IN in) (NP (NP (DT a) (JJ substantial) (NN number)) (PP (IN of) (NP (NN oncology) (NNS indications))))))) (. .))
(S (S (ADVP (RB Additionally)) (, ,) (NP (NP (DT the) (NN tumor)) (NP (JJ somatic) (NN mutation) (NN load))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB associate) (PP (IN with) (NP (NN response))) (PP (IN to) (NP (DT these) (JJ therapeutic) (NNS agents)))))))))) (, ,) (CC and) (S (NP (JJ specific) (JJ mutational) (NNS signatures)) (VP (VBP are) (VP (VBN hypothesized) (S (VP (TO to) (VP (VB improve) (NP (DT this) (NN association))))) (, ,) (PP (VBG including) (NP (NP (NNS signatures)) (VP (VBN related) (PP (IN to) (NP (NN pathogen) (NNS insults))))))))) (. .))
(S (NP (PRP We)) (VP (VBD sought) (S (VP (TO to) (VP (VB study) (UCP (NP (ADVP (FW in) (FW silico)) (NP (DT the) (NN validity)) (PP (IN of) (NP (DT these) (NNS observations)))) (CC and) (SBAR (WHADVP (WRB how)) (S (NP (PRP they)) (VP (VBP relate) (PP (IN to) (NP (DT each) (JJ other))))))))))) (. .))
(S (NP (PRP We)) (ADVP (RB first)) (VP (VBD addressed) (SBAR (IN whether) (S (NP (NP (JJ somatic) (NNS mutations)) (VP (ADVP (RB typically)) (VBN involved) (PP (IN in) (NP (NN cancer))))) (VP (MD may) (VP (VB increase) (, ,) (PP (IN in) (NP (DT a) (ADJP (RB statistically) (JJ meaningful)) (NN manner))) (, ,) (NP (NP (DT the) (NN similarity)) (PP (IN between) (NP (NP (JJ common) (NNS pathogens)) (CC and) (NP (DT the) (JJ human) (NN exome)))))))))) (. .))
(S (NP (PRP$ Our) (NN study)) (VP (VBZ shows) (SBAR (IN that) (S (NP (JJ common) (JJ mutagenic) (NNS processes)) (VP (VP (VBP increase) (, ,) (PP (IN in) (NP (NP (NP (DT the) (JJ upper) (NN range)) (PP (IN of) (NP (ADJP (RB biologically) (JJ plausible)) (NNS frequencies)))) (, ,) (NP (NP (DT the) (NN similarity)) (PP (IN between) (NP (NN cancer) (NNS exomes)))) (CC and) (NP (NP (NN pathogen) (NN DNA)) (PP (IN at) (NP (NP (DT a) (NN scale)) (PP (IN of) (NP (NML (CD 12) (HYPH -) (CD 16)) (NN nucleotide) (NNS sequences))))))))) (CC and) (VP (VBD established) (SBAR (IN that) (S (NP (DT this) (VBN increased) (NN similarity)) (VP (VBZ is) (ADJP (JJ due) (PP (IN to) (NP (NP (DT the) (JJ specific) (NN mutation) (NN distribution)) (PP (IN of) (NP (DT the) (VBN considered) (JJ mutagenic) (NNS processes)))))))))))))) (. .))
(S (ADVP (RB Next)) (, ,) (NP (PRP we)) (VP (VP (VBD studied) (NP (NP (DT the) (NN impact)) (PP (IN of) (NP (NN mutation) (NN rate))))) (CC and) (VP (VBD showed) (SBAR (IN that) (S (S (VP (VBG increasing) (NP (NN mutation) (NN rate)) (ADVP (RB generally)))) (VP (VBZ results) (PP (IN in) (NP (NP (NP (DT an) (VBN increased) (NN similarity)) (PP (IN between) (NP (DT the) (NML (NN cancer) (NN exome) (CC and) (NN pathogen)) (NN DNA)))) (, ,) (PP (IN at) (NP (NP (DT a) (NN scale)) (PP (IN of) (NP (NML (CD 4) (SYM -)) (NML (CD 5) (NN amino)) (NNS acids)))))))))))) (. .))
(S (ADVP (RB Finally)) (, ,) (NP (PRP we)) (VP (VBD investigated) (SBAR (IN whether) (S (NP (DT the) (VBN considered) (JJ mutational) (NNS processes)) (VP (VBP result) (PP (IN in) (NP (NML (NN amino) (HYPH -) (NN acid)) (NNS changes))) (PP (IN with) (NP (NP (JJ functional) (NN relevance)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (RBR more) (JJ likely) (S (VP (TO to) (VP (VB be) (ADJP (JJ immunogenic))))))))))))))) (. .))
(S (NP (PRP We)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (JJ functional) (NN tolerance)) (PP (IN to) (NP (NP (JJ mutagenic) (NNS processes)) (PP (IN across) (NP (NNS species)))))) (ADVP (RB generally)) (VP (VBZ suggests) (NP (JJR more) (NN resilience)) (PP (IN to) (NP (NP (JJ mutagenic) (NNS processes)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ due) (PP (IN to) (NP (NN exposure)))) (PP (IN to) (NP (NP (NNS elements)) (PP (IN of) (NP (NN nature))))) (PP (IN than) (IN to) (NP (NP (JJ mutagenic) (NNS processes)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (ADJP (JJ due) (PP (IN to) (NP (NN exposure)))) (PP (IN to) (NP (ADJP (NN cancer) (HYPH -) (VBG causing)) (JJ artificial) (NNS substances))))))))))))))))) (. .))
(S (NP (DT These) (NNS results)) (VP (VBP support) (NP (DT the) (NN idea)) (SBAR (IN that) (S (NP (NP (NP (NN recognition)) (PP (IN of) (NP (NN pathogen) (NNS sequences)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ differential) (JJ functional) (NN tolerance)) (PP (IN to) (NP (JJ mutagenic) (NNS processes))))) (VP (MD may) (VP (VB play) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NP (DT the) (NML (JJ immune) (NN recognition)) (NN process)) (VP (VBN involved) (PP (IN in) (NP (NN tumor) (NN infiltration))) (PP (IN by) (NP (NNS lymphocytes))))))))))) (. .))
